Results 71 to 80 of about 950,196 (257)

Systemic treatment for hepatocellular carcinoma

open access: yesChronic Diseases and Translational Medicine, 2018
Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and
Manushi Aggarwal   +2 more
doaj   +1 more source

Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. [PDF]

open access: yes, 2011
BackgroundCell migration plays an important role in many physiological and pathological processes, including immune cell chemotaxis and cancer metastasis.
Liao, Kan, Liu, Yang, Wang, Wenqi
core   +2 more sources

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma

open access: yesTuberculosis and Respiratory Diseases, 2016
Somatic mutations that lead to hyperactivation of epidermal growth factor receptor (EGFR) signaling are detected in approximately 50% of lung adenocarcinoma in people from the Far East population and tyrosine kinase inhibitors are now the standard first ...
Y. Chang, Chang-Min Choi, Jae Cheol Lee
semanticscholar   +1 more source

Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)

open access: yesКлиническая онкогематология, 2018
Background. Kinase domain mutations of BCR-ABL gene is the most common cause of tyrosine kinase inhibitor resistance. Aim. To present the data on prognostic value of BCR-ABL mutation burden in Russian patients over the last 10 years.
Vera Vyacheslavovna Tikhonova   +9 more
doaj   +1 more source

Tyrosine kinase inhibition produces specific alterations in axon guidance in the grasshopper embryo [PDF]

open access: yes, 1998
Tyrosine kinase signaling pathways are essential for process outgrowth and guidance during nervous system development. We have examined the roles of tyrosine kinase activity in programming growth cone guidance decisions in an intact nervous system in ...
Menon, Kaushiki P., Zinn, Kai
core  

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]

open access: yes, 2014
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J.   +6 more
core   +1 more source

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model [PDF]

open access: hybrid, 2022
Hiroshi Ikeuchi   +6 more
openalex   +1 more source

Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition

open access: yesFrontiers in Oncology, 2020
Numerous recurrent genetic mutations are known to occur in acute myeloid leukemia (AML). Among these common mutations, Fms-like tyrosine kinase 3 remains as one of the most frequently mutated genes in AML.
Kran Suknuntha   +9 more
doaj   +1 more source

CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation [PDF]

open access: yes, 2003
CD40 is a 48-kDa phosphorylated transmembrane glycoprotein belonging to the TNF receptor superfamily. CD40 has been demonstrated on a range of cell types, and it has an important role in adaptive immunity and inflammation.
Callard, R.E.   +4 more
core  

Rapamycin induces transactivation of the EGFR and increases cell survival. [PDF]

open access: yes, 2009
The mammalian target of rapamycin (mTOR) signaling network regulates cell growth, proliferation and cell survival. Deregulated activation of this pathway is a common event in diverse human diseases such as cancers, cardiac hypertrophy, vascular ...
Chaturvedi, D   +4 more
core   +2 more sources

Home - About - Disclaimer - Privacy